NTRK1 and cholangiocarcinoma: Specifically, this patient had stage IV PLEKHA6‐NTRK1, MET amplified (fold change: 12.3) cholangiocarcinoma which initially responded and then became resistant to the combination therapy with the TRK inhibitor selitrectinib and the type I MET inhibitor crizotinib.